New QP requirements 'in sync with real world', but EU drug industry concerns persist
This article was originally published in SRA
Executive Summary
Pharmaceutical companies have largely welcomed the European Commission's revised draft guideline on qualified person (QP) requirements as the update aims to bring the document in line with the current globalized nature of the drug industry1,2. They are, however, worried about the practical implementation of some of the provisions in the proposed guideline, saying these could lead to unnecessary challenges "while feasible alternatives are at hand".
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.